Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis | Zendy

Adi Cohen | Zendy; Mafo KamandaKosseh | Zendy; Robert R. Recker | Zendy; Joan M. Lappe | Zendy; David W. Dempster | Zendy; Hua Zhou | Zendy; Serge Cremers | Zendy; Mariana Bucovsky | Zendy; Julie Stubby | Zendy; Elizabeth Shane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis

Author(s) -

Adi Cohen,

Mafo KamandaKosseh,

Robert R. Recker,

Joan M. Lappe,

David W. Dempster,

Hua Zhou,

Serge Cremers,

Mariana Bucovsky,

Julie Stubby,

Elizabeth Shane

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-2829

Subject(s) - teriparatide , discontinuation , osteoporosis , medicine , bone density , bone mineral , endocrinology

Without antiresorptive therapy, postmenopausal women lose bone mass after teriparatide (TPTD) discontinuation; estrogen treatment prevents bone loss in this setting. It is not known whether premenopausal women with regular menses lose bone mass after teriparatide discontinuation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research